Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,229

The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.

Malignant glioma: genetics and biology of a grave matter

Open access
Maher, Elizabeth A., Furnari, Frank B., Bachoo, Robert M., Rowitch, David H., Louis, David N., Cavenee, Webster K., DePinho, Ronald A. · 2001 · Genes & Development

Abstract

Malignant brain tumors strike deep into the psyche of those receiving and those delivering the diagnosis. Malignant gliomas, the most common subtype of primary brain tumors, are aggressive, highly invasive, and neurologically destructive tumors considered to be among the deadliest of human cancers. In its most aggressive manifestation, glioblastoma (GBM), median survival ranges from 9 to 12 months, despite maximum treatment efforts—a statistical fact that has changed little over several decades of technological advances in neurosurgery, radiation therapy, and clinical trials of conventional and novel therapeutics. Over the same time period, there has been an explosion of knowledge in cancer biology and basic science discovery that has fueled meaningful progress in the treatment of many common human cancers, including those of the breast, lung, and prostate. It is perplexing that therapies used effectively in the treatment of these solid tumors are overwhelmingly ineffective in the treatment of GBM, perhaps reflecting the eccentric biology and cellular origin of this neoplasm. To date, only one new agent has been documented to have modest activity against intermediate-grade gliomas, whereas no effective agents have emerged for the treatment of GBM, despite 20 years of enrolling patients in clinical trials. It is ironic that although a comprehensive view of the genetic lesions encountered in malignant gliomas has been compiled, substantive conceptual and practical barriers remain in assigning functional significance to these genetic changes and in harnessing this basic information into the development of drugs that make a difference in patient care. The history of treating malignant gliomas dates back to the middle of the 19th century and parallels landmark advances in modern surgical technique and the clinical discipline of neurology. The first brain tumor surgery of the modern era was performed in 1884 by Rickman

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/gad.891601

Cites

195 of 195 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 25

  1. Al-Awqati, 1999, Terminal differentiation in epithelia: The Hensin pathway in intercalated cells., Semin. Nephrol., 19, 415
  2. Biernat, 1995, Identical mutations of the p53 tumor supressor gene in the gliomatous and the sarcomatous components of gliosarcomas suggest a common origin from glial cells., J. Neuropathol. Exp. Neurol., 54, 651, 10.1097/00005072-199509000-00006 · doi:10.1097/00005072-199509000-00006
  3. Bouchard, 1960, Radiation therapy in the management of neoplasms of the central nervous system, with a special note in regard to children: Twenty years experience., Am. J. Roentgenol., 84, 610
  4. 10.1016/0006-8993(85)90802-9 · doi:10.1016/0006-8993(85)90802-9
  5. 10.1002/(SICI)1097-4547(19980901)53:5<521::AID-JNR2>3.0.CO;2-B · doi:10.1002/(sici)1097-4547(19980901)53:5<521::aid-jnr2>3.0.co;2-b
  6. 10.1006/exnr.2000.7482 · doi:10.1006/exnr.2000.7482
  7. 10.1046/j.1471-4159.2000.0741393.x · doi:10.1046/j.1471-4159.2000.0741393.x
  8. Heldin, 1996, Protein tyrosine kinase receptors., Cancer Surveys, 27, 7
  9. 10.1002/(SICI)1098-2264(199805)22:1<9::AID-GCC2>3.0.CO;2-1 · doi:10.1002/(sici)1098-2264(199805)22:1<9::aid-gcc2>3.0.co;2-1
  10. James, 1991, Chromosome 9 deletion mapping reveals interferon α and interferon β-1 gene deletions in human glial tumors., Cancer Res., 51, 1684
  11. McKeever, 1991, Patterns of antigenic expression of human glioma cells., Crit. Rev. Neurobiol., 6, 119
  12. 10.1002/(SICI)1098-1136(199701)19:1<85::AID-GLIA9>3.0.CO;2-9 · doi:10.1002/(sici)1098-1136(199701)19:1<85::aid-glia9>3.0.co;2-9
  13. Mishima, K., Nagane, M., Lin, H., Cavenee, W., and Huang, H.J.S. 1999. Expression of a specific mutant epidermal growth factor receptor mediates glioma cell invasion in vivo. Proc. Am. Assoc. Cancer Res.: 519..
  14. 10.1007/BF00713052 · doi:10.1007/bf00713052
  15. Mueller, 2001, Clonal analysis in glioblastoma with epithelial differentation., Brain Pathol., 11, 39, 10.1111/j.1750-3639.2001.tb00379.x · doi:10.1111/j.1750-3639.2001.tb00379.x
  16. Quelle, 1995, Cloning and characterization of murine p16INK4a and p15INK4b genes., Oncogene, 11, 635
  17. Rubio, 1994, Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas., Cancer Res., 54, 45
  18. 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U · doi:10.1002/(sici)1521-1878(199810)20:10<808::aid-bies6>3.0.co;2-u
  19. 10.1002/(SICI)1098-1136(199903)26:1<22::AID-GLIA3>3.0.CO;2-M · doi:10.1002/(sici)1098-1136(199903)26:1<22::aid-glia3>3.0.co;2-m
  20. Small R.K. (1992) Glial cell lineages in development and disease. in Disease of the nervous system: Clinical Neurobiology, eds Ashurry A.K. McKhann G.M. McDonald W.I. (W.B. Saunders Company, Philadelphia), pp 72–86.
  21. Smith, J.S., Tachibana, I., Pohl, U., Lee, H.K., Thanarajasigam, U., Portier, B.P., Ueki, K., Ramaswamy, S., Billings, S.J., Mohrenweiser, H.W., et al. 2000. A transcript map of the chromosome 19 q-arm tumor supressor region. Genomics , in press.. · doi:10.1006/geno.1999.6101
  22. Takito, 1999, Hensin, the polarity reversal protein, is encoded by DMBT1, a gene frequently deleted in malignant gliomas., Am. J. Physiol., 277, F277
  23. Tsai, 2000, Cell contact regulates fate choice by cortical stem cells., J. Neurosci., 20, 3725, 10.1523/JNEUROSCI.20-10-03725.2000 · doi:10.1523/jneurosci.20-10-03725.2000
  24. 10.1002/(SICI)1097-0215(20000201)85:3<398::AID-IJC17>3.0.CO;2-L · doi:10.1002/(sici)1097-0215(20000201)85:3<398::aid-ijc17>3.0.co;2-l
  25. 10.1006/geno.1995.9972 · doi:10.1006/geno.1995.9972

Cited by

See all 1,229

Metadata

Authors
Maher, E. A., Furnari, F. B., Bachoo, R. M., Rowitch, D. H., Louis, D. N., Cavenee, W. K., & DePinho, R. A.
Venue
Genes & Development
Published
2001-06-01
Volume
15
Issue
11
Pages
1311-1333
ISSN
  • 0890-9369 (ISSN-L)
  • 1549-5477
OpenAlex
W2114998237
Cited by
1,229
References
195
Type
posted content
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.